Kelland L R, Mistry P, Abel G, Loh S Y, O'Neill C F, Murrer B A, Harrap K R
Drug Development Section, Institute of Cancer Research, Sutton, Surrey, England.
Cancer Res. 1992 Jul 15;52(14):3857-64.
Acquired resistance to cisplatin has been generated in vitro in two human ovarian carcinoma cell lines: 41M, established from a previously untreated patient; and CH1, from a patient previously treated with cisplatin and cis-diammine-1,1-cyclobutane dicarboxylatoplatinum(II) (carboplatin). In neither cell line with acquired resistance did intracellular detoxification (via increased glutathione or metallothioneins) appear to be a major determinant of resistance. Resistance in 41McisR (resistance factor of 4.7) appeared to be due predominantly to a reduced platinum accumulation (levels were only 23.8% in 41McisR versus 41M). This was also reflected at the DNA level by a similar level of reduced DNA interstrand cross-links and total platinum-DNA adducts measured immediately after a 2-h exposure to cisplatin in 41McisR versus 41M. Conversely, for CH1cisR (resistance factor of 6.5), platinum accumulation, and initial numbers of DNA-interstrand cross-links and total DNA-platinum adducts were not significantly different from the parent CH1 line. This is suggestive of a resistance mechanism involving increased DNA repair or tolerance to platinum-DNA adducts operating in the CH1cisR/CH1 pair of lines. Cross-resistance to carboplatin and partial cross-resistance to the 1,2-diaminocyclohexane-containing agent, (trans-d,l)-1,2-diaminocyclohexane tetrachloroplatinum(IV) (tetraplatin), was observed in both pairs. However, two novel platinum(IV) ammine/amine dicarboxylates, ammine dibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) and ammine dibenzoatodichloro(propylamine)platinum(IV) (JM244), completely circumvented resistance in 41McisR to produce some collateral sensitivity (resistance factors of 0.67 and 0.54, respectively) but showed cross-resistance in CH1cisR (resistance factors of 3.7 and 4.6). In contrast to the data for cisplatin, intracellular platinum levels were not significantly different between the 41M and 41McisR pair of cell lines after exposure to JM244. These results suggest that the ammine/amine platinum(IV) dicarboxylates, which show considerably greater in vitro cytotoxicity than cisplatin, are capable of circumventing acquired cisplatin resistance which is due to decreased intracellular accumulation but are not able to overcome resistance at the level of DNA platination and removal.
41M,源自一名未经治疗的患者;以及CH1,源自一名先前接受过顺铂和顺 - 二胺 - 1,1 - 环丁烷二羧酸铂(II)(卡铂)治疗的患者。在这两种获得性耐药的细胞系中,细胞内解毒(通过增加谷胱甘肽或金属硫蛋白)似乎都不是耐药的主要决定因素。41McisR(耐药因子为4.7)中的耐药似乎主要是由于铂积累减少(41McisR中的水平仅为41M的23.8%)。在DNA水平上也反映了这一点,在41McisR与41M中,在暴露于顺铂2小时后立即测量的DNA链间交联减少水平和总铂 - DNA加合物水平相似。相反,对于CH1cisR(耐药因子为6.5),铂积累以及DNA链间交联和总DNA - 铂加合物的初始数量与亲本CH1细胞系没有显著差异。这表明在CH1cisR/CH1细胞系对中存在一种涉及DNA修复增加或对铂 - DNA加合物耐受性增加而发挥作用的耐药机制。在这两种细胞系对中均观察到对卡铂的交叉耐药以及对含1,2 - 二氨基环己烷的药物(反式 - d,l)-1,2 - 二氨基环己烷四氯铂(IV)(四铂)的部分交叉耐药。然而,两种新型铂(IV)胺/胺二羧酸盐,氨二丁酸二氯(环己胺)铂(IV)(JM221)和氨二苯甲酸二氯(丙胺)铂(IV)(JM244),完全克服了41McisR中的耐药性,产生了一些协同敏感性(耐药因子分别为0.67和0.54),但在CH1cisR中表现出交叉耐药(耐药因子为3.7和4.6)。与顺铂的数据相反,在暴露于JM244后,41M和41McisR细胞系对之间的细胞内铂水平没有显著差异。这些结果表明,胺/胺铂(IV)二羧酸盐在体外显示出比顺铂更大的细胞毒性,能够克服由于细胞内积累减少而导致的获得性顺铂耐药,但无法在DNA铂化和去除水平克服耐药性。